Misplaced Pages

Lifastuzumab vedotin

Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	phosphate-sodium cotransporter
Clinical data
Other names	DNIB0600A
ATC code	none
Identifiers
CAS Number	1401812-88-1
ChemSpider	none
UNII	7IUT83FK6S
KEGG	D11238
Chemical and physical data
Formula	C6504H10028N1744O2018S46
Molar mass	146416.72 g·mol

Lifastuzumab vedotin (INN; development code DNIB0600A) is an experimental monoclonal antibody-drug conjugate designed for the treatment of cancer.

This drug was developed by Genentech/Roche.

References

1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
2. Statement On A Nonproprietary Name Adopted By The USAN Council - Lifastuzumab Vedotin, American Medical Association.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibody stubs
• Experimental cancer drugs
• Monoclonal antibodies for tumors
• Antibody-drug conjugates